Maggie L. Shaw

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

The Rutgers School of Public Health dean reflects on activism, apathy, and the road to treatment.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.

Seven oncology leaders reflect on lasting gains in patient care, cost awareness, and collaboration, and what was lost when CMS walked away.

Swarup Kumar, MD, discusses how myeloma programs can bridge gaps between academic innovation and community access for bispecific antibody therapy.

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

Emily K. Curran, MD, discusses how newer ALL therapies are reshaping treatment decisions and minimal residual disease monitoring for older adults.

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

Kerry Rogers, MD, outlines the cardiovascular risks of prolonged BTK inhibitor therapy in CLL and the major sequencing questions that remain unanswered.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them.

The 2 risks operate independently so that social interventions can reduce disease risk regardless of a patient’s genetic profile.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

The message rate tripled, rising by 153% from 2020 to 2025, adding clinician workload and exposing equity gaps that managed care must address.

The myeloma space has undergone tremendous transformation recently, says Prerna Mewawalla, MD, including CAR T-cell therapies and bispecific antibodies.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

Perry Halkitis, PhD, MS, MPH, draws on decades of epidemic response to argue for evidence-based policy, public trust, and equitable care delivery.

After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and clinical framework it demands.

Organized screening in Hong Kong narrowed socioeconomic disparities over 9 years, although suboptimal uptake persists in key groups.

Phlebotomy is used in polycythemia vera to reduce hematocrit levels below 45%, and is the most common treatment for the myeloproliferative neoplasm.

As GLP-1 approvals expand into new indications, claims data reveal most treated patients already qualify under multiple indications.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

Bridget Vazquez, PsyD, breaks down how cancer-related PTSD manifests, why it goes unrecognized, and what patients, caregivers, and clinicians can do.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and what to do about them.